These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

572 related items for PubMed ID: 24107103

  • 1. Strain dependence of diet-induced NASH and liver fibrosis in obese mice is linked to diabetes and inflammatory phenotype.
    Farrell GC, Mridha AR, Yeh MM, Arsov T, Van Rooyen DM, Brooling J, Nguyen T, Heydet D, Delghingaro-Augusto V, Nolan CJ, Shackel NA, McLennan SV, Teoh NC, Larter CZ.
    Liver Int; 2014 Aug; 34(7):1084-93. PubMed ID: 24107103
    [Abstract] [Full Text] [Related]

  • 2. Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice.
    Larter CZ, Yeh MM, Van Rooyen DM, Teoh NC, Brooling J, Hou JY, Williams J, Clyne M, Nolan CJ, Farrell GC.
    J Gastroenterol Hepatol; 2009 Oct; 24(10):1658-68. PubMed ID: 19788606
    [Abstract] [Full Text] [Related]

  • 3. TLR9 is up-regulated in human and murine NASH: pivotal role in inflammatory recruitment and cell survival.
    Mridha AR, Haczeyni F, Yeh MM, Haigh WG, Ioannou GN, Barn V, Ajamieh H, Adams L, Hamdorf JM, Teoh NC, Farrell GC.
    Clin Sci (Lond); 2017 Aug 15; 131(16):2145-2159. PubMed ID: 28687713
    [Abstract] [Full Text] [Related]

  • 4. Dietary modification dampens liver inflammation and fibrosis in obesity-related fatty liver disease.
    Larter CZ, Yeh MM, Haigh WG, Van Rooyen DM, Brooling J, Heydet D, Nolan CJ, Teoh NC, Farrell GC.
    Obesity (Silver Spring); 2013 Jun 15; 21(6):1189-99. PubMed ID: 23666886
    [Abstract] [Full Text] [Related]

  • 5. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
    Larter CZ, Yeh MM, Van Rooyen DM, Brooling J, Ghatora K, Farrell GC.
    J Gastroenterol Hepatol; 2012 Feb 15; 27(2):341-50. PubMed ID: 21929649
    [Abstract] [Full Text] [Related]

  • 6. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M, Bukong TN, Csak T, Saha B, Park JK, Ambade A, Kodys K, Szabo G.
    J Transl Med; 2015 Jun 16; 13():193. PubMed ID: 26077675
    [Abstract] [Full Text] [Related]

  • 7. Endoplasmic reticulum stress does not contribute to steatohepatitis in obese and insulin-resistant high-fat-diet-fed foz/foz mice.
    Legry V, Van Rooyen DM, Lambert B, Sempoux C, Poekes L, Español-Suñer R, Molendi-Coste O, Horsmans Y, Farrell GC, Leclercq IA.
    Clin Sci (Lond); 2014 Oct 16; 127(7):507-18. PubMed ID: 24766485
    [Abstract] [Full Text] [Related]

  • 8. Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome.
    Van Rooyen DM, Gan LT, Yeh MM, Haigh WG, Larter CZ, Ioannou G, Teoh NC, Farrell GC.
    J Hepatol; 2013 Jul 16; 59(1):144-52. PubMed ID: 23500152
    [Abstract] [Full Text] [Related]

  • 9. Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice.
    Arsov T, Larter CZ, Nolan CJ, Petrovsky N, Goodnow CC, Teoh NC, Yeh MM, Farrell GC.
    Biochem Biophys Res Commun; 2006 Apr 21; 342(4):1152-9. PubMed ID: 16516152
    [Abstract] [Full Text] [Related]

  • 10. Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western Diet.
    Ganguly S, Muench GA, Shang L, Rosenthal SB, Rahman G, Wang R, Wang Y, Kwon HC, Diomino AM, Kisseleva T, Soorosh P, Hosseini M, Knight R, Schnabl B, Brenner DA, Dhar D.
    Cell Mol Gastroenterol Hepatol; 2021 Apr 21; 12(3):891-920. PubMed ID: 34062281
    [Abstract] [Full Text] [Related]

  • 11. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis.
    Van Rooyen DM, Larter CZ, Haigh WG, Yeh MM, Ioannou G, Kuver R, Lee SP, Teoh NC, Farrell GC.
    Gastroenterology; 2011 Oct 21; 141(4):1393-403, 1403.e1-5. PubMed ID: 21703998
    [Abstract] [Full Text] [Related]

  • 12. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
    Mridha AR, Wree A, Robertson AAB, Yeh MM, Johnson CD, Van Rooyen DM, Haczeyni F, Teoh NC, Savard C, Ioannou GN, Masters SL, Schroder K, Cooper MA, Feldstein AE, Farrell GC.
    J Hepatol; 2017 May 21; 66(5):1037-1046. PubMed ID: 28167322
    [Abstract] [Full Text] [Related]

  • 13. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis.
    Barreyro FJ, Holod S, Finocchietto PV, Camino AM, Aquino JB, Avagnina A, Carreras MC, Poderoso JJ, Gores GJ.
    Liver Int; 2015 Mar 21; 35(3):953-66. PubMed ID: 24750664
    [Abstract] [Full Text] [Related]

  • 14. The FATZO mouse, a next generation model of type 2 diabetes, develops NAFLD and NASH when fed a Western diet supplemented with fructose.
    Sun G, Jackson CV, Zimmerman K, Zhang LK, Finnearty CM, Sandusky GE, Zhang G, Peterson RG, Wang YJ.
    BMC Gastroenterol; 2019 Mar 18; 19(1):41. PubMed ID: 30885145
    [Abstract] [Full Text] [Related]

  • 15. Galectin-3 and IL-33/ST2 axis roles and interplay in diet-induced steatohepatitis.
    Pejnovic N, Jeftic I, Jovicic N, Arsenijevic N, Lukic ML.
    World J Gastroenterol; 2016 Nov 28; 22(44):9706-9717. PubMed ID: 27956794
    [Abstract] [Full Text] [Related]

  • 16. Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice.
    Nan YM, Fu N, Wu WJ, Liang BL, Wang RQ, Zhao SX, Zhao JM, Yu J.
    Scand J Gastroenterol; 2009 Nov 28; 44(3):358-65. PubMed ID: 18991162
    [Abstract] [Full Text] [Related]

  • 17. Short-term therapy with peroxisome proliferation-activator receptor-alpha agonist Wy-14,643 protects murine fatty liver against ischemia-reperfusion injury.
    Teoh NC, Williams J, Hartley J, Yu J, McCuskey RS, Farrell GC.
    Hepatology; 2010 Mar 28; 51(3):996-1006. PubMed ID: 20131406
    [Abstract] [Full Text] [Related]

  • 18. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS, Kristiansen MN, Hansen HH, Veidal SS, Rigbolt KT, Gillum MP, Jelsing J, Vrang N, Feigh M.
    World J Gastroenterol; 2018 Jan 14; 24(2):179-194. PubMed ID: 29375204
    [Abstract] [Full Text] [Related]

  • 19. Differential Immunometabolic Phenotype in Th1 and Th2 Dominant Mouse Strains in Response to High-Fat Feeding.
    Jovicic N, Jeftic I, Jovanovic I, Radosavljevic G, Arsenijevic N, Lukic ML, Pejnovic N.
    PLoS One; 2015 Jan 14; 10(7):e0134089. PubMed ID: 26218873
    [Abstract] [Full Text] [Related]

  • 20. Aerobic exercise training in the treatment of non-alcoholic fatty liver disease related fibrosis.
    Linden MA, Sheldon RD, Meers GM, Ortinau LC, Morris EM, Booth FW, Kanaley JA, Vieira-Potter VJ, Sowers JR, Ibdah JA, Thyfault JP, Laughlin MH, Rector RS.
    J Physiol; 2016 Sep 15; 594(18):5271-84. PubMed ID: 27104887
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.